Development of a Stable MGAT1− CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies
The high rate of new HIV infections, particularly in Sub-Saharan Africa, emphasizes the need for a safe and effective vaccine to prevent acquired immunodeficiency syndrome (AIDS). To date, the only HIV vaccine trial that has exhibited protective efficacy in humans was the RV144 study completed in Th...
Main Authors: | Rachel C. Doran, Bin Yu, Meredith Wright, Sara M. O'Rourke, Lu Yin, Jennie M. Richardson, Gabriel Byrne, Kathryn A. Mesa, Phillip W. Berman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02313/full |
Similar Items
-
Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies
by: Jennie M. Hutchinson, et al.
Published: (2019-05-01) -
gp120 Immunogen Design And Characterization
by: Chakraborty, Kausik
Published: (2011) -
Characterization of RNA aptamers that bind to HIV-1 gp120
by: Cohen, Carla J.
Published: (2006) -
HIV-1 Envelope Protein gp120 Promotes Proliferation and the Activation of Glycolysis in Glioma Cell
by: Gabriel Valentín-Guillama, et al.
Published: (2018-09-01) -
The expression, purification and characterisation of recombinant HIV-1 subtype C gp120
by: Michler, Katherine Laura
Published: (2008)